Pharmacological inhibition of CDK12 significantly reduced viability in endocrine resistant and metastatic cell and organoid models in vitro, and decreased metastatic spread in vivo.<h4>Conclusion</h4>This work describes a novel mechanism for CDK12, suggesting a potential vulnerability in ER+ breast cancer. Here, ESR1 is linked to breast carcinoma.